Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 90.8% in May

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 75,959 shares, a drop of 90.8% from the April 30th total of 821,485 shares. Based on an average trading volume of 703,441 shares, the days-to-cover ratio is currently 0.1 days. Approximately 6.2% of the company’s shares are short sold.

Institutional Trading of Aspire Biopharma

A number of institutional investors have recently bought and sold shares of ASBP. Jane Street Group LLC boosted its position in shares of Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Aspire Biopharma during the 3rd quarter worth about $28,000. Finally, XTX Topco Ltd raised its position in shares of Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares in the last quarter. 19.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Aspire Biopharma Stock Down 7.9%

Shares of Aspire Biopharma stock opened at $4.67 on Thursday. The business’s fifty day simple moving average is $15.99 and its 200-day simple moving average is $63.48. The firm has a market cap of $6.05 million, a PE ratio of -0.04 and a beta of 0.21. Aspire Biopharma has a 52 week low of $3.31 and a 52 week high of $1,050.36.

Aspire Biopharma (NASDAQ:ASBP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($20.57) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million for the quarter.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.